{"id":56143,"date":"2026-02-03T16:25:44","date_gmt":"2026-02-03T08:25:44","guid":{"rendered":"https:\/\/flcube.com\/?p=56143"},"modified":"2026-02-03T16:25:45","modified_gmt":"2026-02-03T08:25:45","slug":"chiesis-juxtapid-wins-nmpa-approval-for-rare-cholesterol-disorder-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56143","title":{"rendered":"Chiesi&#8217;s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China"},"content":{"rendered":"\n<p><strong>Chiesi Group&#8217;s China unit<\/strong> announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has granted marketing approval for <strong>Juxtapid (lomitapide)<\/strong> for the treatment of <strong>homozygous familial hypercholesterolemia (HoFH)<\/strong> in adult patients. The <strong>microsomal triglyceride transfer protein (MTP) inhibitor<\/strong> provides a new therapeutic option for patients who struggle to achieve lipid targets with conventional therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Chiesi Group (China unit)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Juxtapid (lomitapide)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Microsomal triglyceride transfer protein (MTP) inhibitor<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA marketing authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>HoFH in adults (combination with low-fat diet and other lipid-lowering therapies)<\/td><\/tr><tr><td><strong>Key Efficacy<\/strong><\/td><td>Reduces LDL-C, total cholesterol, apo B, and non-HDL-C<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>Lipid-lowering effect independent of LDL receptor activity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-clinical-advantage\">Mechanism of Action &amp; Clinical Advantage<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MTP Inhibition:<\/strong> Lomitapide blocks MTP within hepatocytes and intestinal epithelial cells, preventing assembly of apo B\u2011containing VLDL and chylomicrons<\/li>\n\n\n\n<li><strong>LDLR Independence:<\/strong> Works effectively even in HoFH patients with extremely low or absent residual LDL receptor function<\/li>\n\n\n\n<li><strong>Additive Effect:<\/strong> Provides additional LDL\u2011C control on top of standard treatment through a different mechanism than statins or PCSK9 inhibitors<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Addresses HoFH patients who have long struggled to achieve treatment targets, offering new potential for improving long-term prognosis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HoFH Prevalence:<\/strong> Estimated <strong>1,000\u20132,000<\/strong> patients in China; global prevalence of <strong>1 in 250,000<\/strong><\/li>\n\n\n\n<li><strong>China Rare Disease Market:<\/strong> Valued at <strong>\u00a530\u202fbillion<\/strong> : (~US$4.2\u202fbillion) in 2025, growing rapidly with improved diagnosis and orphan drug policies<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> HoFH drugs command premium pricing; Juxtapid could generate <strong>\u00a5300\u2013500\u202fmillion<\/strong> : (US$42\u201370\u202fmillion) peak annual sales<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>evinacumab (Regeneron)<\/strong> and <strong>lomitapide (Aegerion)<\/strong>; Chiesi\u2019s local manufacturing and regulatory expertise offers market access advantage<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens Chiesi\u2019s rare disease portfolio in China; validates MTP inhibition approach for severe lipid disorders<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Commercial launch expected <strong>Q2\u202f2026<\/strong>; patient access programs to be established for HoFH community<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market penetration, and revenue projections for Juxtapid. Actual results may differ due to competitive dynamics, pricing negotiations, and patient access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chiesi Group&#8217;s China unit announced that the National Medical Products Administration (NMPA) has granted marketing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56144,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1919,15],"class_list":["post-56143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-chiesi-farmaceutici","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chiesi&#039;s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chiesi Group&#039;s China unit announced that the National Medical Products Administration (NMPA) has granted marketing approval for Juxtapid (lomitapide) for the treatment of homozygous familial hypercholesterolemia (HoFH) in adult patients. The microsomal triglyceride transfer protein (MTP) inhibitor provides a new therapeutic option for patients who struggle to achieve lipid targets with conventional therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56143\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chiesi&#039;s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China\" \/>\n<meta property=\"og:description\" content=\"Chiesi Group&#039;s China unit announced that the National Medical Products Administration (NMPA) has granted marketing approval for Juxtapid (lomitapide) for the treatment of homozygous familial hypercholesterolemia (HoFH) in adult patients. The microsomal triglyceride transfer protein (MTP) inhibitor provides a new therapeutic option for patients who struggle to achieve lipid targets with conventional therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56143\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T08:25:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T08:25:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chiesi&#8217;s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China\",\"datePublished\":\"2026-02-03T08:25:44+00:00\",\"dateModified\":\"2026-02-03T08:25:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143\"},\"wordCount\":347,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0302.webp\",\"keywords\":[\"Chiesi Farmaceutici\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56143#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56143\",\"name\":\"Chiesi's Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0302.webp\",\"datePublished\":\"2026-02-03T08:25:44+00:00\",\"dateModified\":\"2026-02-03T08:25:45+00:00\",\"description\":\"Chiesi Group's China unit announced that the National Medical Products Administration (NMPA) has granted marketing approval for Juxtapid (lomitapide) for the treatment of homozygous familial hypercholesterolemia (HoFH) in adult patients. The microsomal triglyceride transfer protein (MTP) inhibitor provides a new therapeutic option for patients who struggle to achieve lipid targets with conventional therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56143\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0302.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chiesi's Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56143#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chiesi&#8217;s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chiesi's Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China - Insight, China&#039;s Pharmaceutical Industry","description":"Chiesi Group's China unit announced that the National Medical Products Administration (NMPA) has granted marketing approval for Juxtapid (lomitapide) for the treatment of homozygous familial hypercholesterolemia (HoFH) in adult patients. The microsomal triglyceride transfer protein (MTP) inhibitor provides a new therapeutic option for patients who struggle to achieve lipid targets with conventional therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56143","og_locale":"en_US","og_type":"article","og_title":"Chiesi's Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China","og_description":"Chiesi Group's China unit announced that the National Medical Products Administration (NMPA) has granted marketing approval for Juxtapid (lomitapide) for the treatment of homozygous familial hypercholesterolemia (HoFH) in adult patients. The microsomal triglyceride transfer protein (MTP) inhibitor provides a new therapeutic option for patients who struggle to achieve lipid targets with conventional therapies.","og_url":"https:\/\/flcube.com\/?p=56143","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-03T08:25:44+00:00","article_modified_time":"2026-02-03T08:25:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56143#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56143"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chiesi&#8217;s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China","datePublished":"2026-02-03T08:25:44+00:00","dateModified":"2026-02-03T08:25:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56143"},"wordCount":347,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56143#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0302.webp","keywords":["Chiesi Farmaceutici","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56143#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56143","url":"https:\/\/flcube.com\/?p=56143","name":"Chiesi's Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56143#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56143#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0302.webp","datePublished":"2026-02-03T08:25:44+00:00","dateModified":"2026-02-03T08:25:45+00:00","description":"Chiesi Group's China unit announced that the National Medical Products Administration (NMPA) has granted marketing approval for Juxtapid (lomitapide) for the treatment of homozygous familial hypercholesterolemia (HoFH) in adult patients. The microsomal triglyceride transfer protein (MTP) inhibitor provides a new therapeutic option for patients who struggle to achieve lipid targets with conventional therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56143#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56143"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56143#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0302.webp","width":1080,"height":608,"caption":"Chiesi's Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56143#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chiesi&#8217;s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56143"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56143\/revisions"}],"predecessor-version":[{"id":56145,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56143\/revisions\/56145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56144"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}